Longevity Vision Fund invests in technologies that have the potential to disrupt life sciences and extend healthy lifespan.
Longevity Vision Fund is a $100M investment fund dedicated to making longevity affordable and accessible to all. The fund accelerates longevity breakthroughs by investing in companies that develop technologies, products, and services that extend healthy human lifespans and overcome the negative effects of agingLongevity Vision Fund provides Seed to Series C funding to biotech and life extension-focused companies that have demonstrated affordable longevity potential and vision of milestones driving up the value of the company and market validation.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Apr 19, 2022
Tessera Therapeutics
|
Series C | $300M | Biopharma | — |
Jan 12, 2021
Tessera Therapeutics
|
Series B | $230M | Biopharma | — |
Nov 9, 2020
Eko
|
Series C | $65M | Artificial Intelligence | — |
Jul 24, 2019
Freenome
|
Series B | $160M | Biotechnology | — |